FDA/CDC
FDA/CDC
FDA Okays Abuse-Deterrent Opioid for Severe Pain
This new immediate-release formulation of oxycodone hydrochloride is made with a proprietary technology that makes it harder for people to crush,...
Latest News
FDA Initiative Aims to Improve Diversity in Clinical Trials
This initiative could be a critical step toward ensuring diversity in major clinical trials after years of stagnation, Dr. Valerie Harvey said.
FDA/CDC
FDA Issues New Guidance for Early Alzheimer’s Drug Development
The FDA noted that a key principle in developing guidance for early Alzheimer’s disease therapies is that treatment “must begin before there are...
News from the FDA/CDC
FDA Removes Harmful Chemicals From Food Packaging
The “major source of dietary exposure to PFAS from food packaging” is being eliminated.
News from the FDA/CDC
FDA Recommends DEA Move Cannabis From Schedule I to III
The FDA said in its report that cannabis is a low-risk threat to public health.
FDA/CDC
FDA Investigates Three Side Effects Reported With Weight Loss Drugs
FDA evaluating alopecia, aspiration, or suicidal ideation side effects which have been reported with weight loss medications.
FDA/CDC
FDA panel unanimously endorses lecanemab for Alzheimer’s
An intravenous infusion targeting amyloid-beta, lecanemab received accelerated FDA approved earlier in 2023 for the treatment of early Alzheimer’s...
FDA/CDC
CMS to cover Alzheimer’s drugs after traditional FDA okay
“If the FDA grants traditional approval, CMS is prepared to ensure anyone with Medicare Part B who meets the criteria is covered.”
News from the FDA/CDC
FDA approves buprenorphine injection for opioid use disorder
Brixadi is approved in both weekly and monthly subcutaneous injectable formulations at varying doses.
FDA/CDC
FDA approves first drug to treat Alzheimer’s agitation
“Agitation is one of the most common and challenging aspects of care among patients with dementia due to Alzheimer’s disease.”
News from the FDA/CDC
FDA moves to stop the spread of illicit ‘tranq’ in the U.S.
The agency “remains concerned about the increasing prevalence of xylazine mixed with illicit drugs,” said FDA Commissioner Robert M. Califf, MD....